for treatment of malignant Pleural Mesothelioma, a type of tumor of the lining of the lung, in combination with cisplatin for patients whose disease is either unresectable or who are not othenvise candidates for curative surgery. As a first-line treatment, in combination with cisplatin, against locally-advanced and metastatic non-small cell lung cancer (NSCLC) in patients with non-squamous histology. A Phase 111 study showed benefits of maintenance use of pemetrexed for non-squamous NSCLC. Trials are currently testing it against esophagus and other cancers.
Vial
11319 EGP
for treatment of malignant Pleural Mesothelioma, a type of tumor of the lining of the lung, in combination with cisplatin for patients whose disease is either unresectable or who are not othenvise candidates for curative surgery. As a first-line treatment, in combination with cisplatin, against locally-advanced and metastatic non-small cell lung cancer (NSCLC) in patients with non-squamous histology. A Phase 111 study showed benefits of maintenance use of pemetrexed for non-squamous NSCLC. Trials are currently testing it against esophagus and other cancers.
Note: All the provided information about this drug does not substitute for consulting a doctor.